Inactive Instrument

Grindeks AS Share Price Nasdaq Riga

GRD1R

LV0000100659

Pharmaceuticals

End-of-day quote Nasdaq Riga
- ^LVL	-

03/04/24	Grindeks Opens New Subsidiaries Worldwide	CI
24/02/21	JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	CI

Grindeks is the Baltic leader pharmaceutical group. Net sales break down by activity as follows: - research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.; - production of pharmaceutical active ingredients (5.1%). Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).

Employees

Sector

Pharmaceuticals

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

03/04/24	Grindeks Opens New Subsidiaries Worldwide	CI
24/02/21	JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	CI
21/01/21	SIA Liplat Holding completed the acquisition of additional 2.6% stake in Akciju sabiedriba Grindeks for €3.4 million.	CI
21/12/20	SIA Liplat Holding made an offer to acquire the remaining 5.84% stake in Akciju sabiedriba Grindeks for €7.6 million.	CI
26/11/20	Akciju Sabiedriba Grindeks Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
27/08/20	Akciju Sabiedriba Grindeks Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
18/08/20	Akciju sabiedriba Grindeks Approves to Pay Dividend, Payable on September 17, 2020	CI
04/08/20	Akciju sabiedriba Grindeks Proposes to Pay Dividend, Payable on September 17, 2020 and November 17, 2020, Respectively	CI
05/03/20	Grindeks Completes Phase 1 Clinical Study of its New Investigational Medicinal Product Methyl-GBB	CI
28/02/20	As Grindeks Reports Earnings Results for the Full Year Ended December 31, 2019	CI
04/02/20	JSC Grindeks Announces Appointment of Juris Hmelnickis as the Chairman of the Board	CI
22/01/20	JSC Grindeks Announces Resignation of Juris Bundulis as Chairman of the Board	CI
19/12/19	JSC Grindeks Receives A Certificate of Saudi Food and Drug Authority	CI

03/03/21	Grindeks : In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit	AQ
24/02/21	Grindeks : Andrejs Liberts appointed as the member of the board of JSC “Grindeks”	AQ
12/02/21	Grindeks : Delisting of AS „Grindeks” shares from the Baltic Main list	AQ
09/02/21	Grindeks : On exclusion of shares from the regulated market	AQ
26/01/21	Grindeks : Information about refusal to repurchase the final shares of JSC “Grindeks”	AQ

Manager	Title	Age	Since
Janis Romanovskis CEO	Chief Executive Officer	66	21/04/2010
Andrejs Liberts PRN	Corporate Officer/Principal	41	23/02/2021
Iveta Zomerfelde SAM	Sales & Marketing	-	02/03/2015

Director	Title	Age	Since
Kirovs Lipmans CHM	Chairman	85	31/12/2002
Anna Lipmane BRD	Director/Board Member	78	31/12/2007
Filips Lipmans BRD	Director/Board Member	48	31/12/2003

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.08%	-1.43%	+15.99%	+67.26%	47.71B
OTSUKA HOLDINGS CO., LTD.	-3.21%	+1.37%	+52.36%	+125.75%	40.3B
CIPLA LIMITED	-0.40%	-1.23%	-10.08%	+16.08%	12.09B
ZYDUS LIFESCIENCES LIMITED	+1.11%	-1.34%	+13.61%	+71.49%	11.68B
KRKA, D. D.	0.00%	+0.58%	+30.65%	+148.80%	9.19B
GEDEON RICHTER	-0.39%	-0.92%	+19.81%	+39.54%	7.57B
ONO PHARMACEUTICAL CO., LTD.	-1.35%	+0.74%	+47.03%	-11.93%	7.24B
GLENMARK PHARMACEUTICALS LIMITED	-0.64%	-0.02%	+19.42%	+199.06%	6.84B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-5.36%	-6.36%	-36.28%	+18.28%	5.42B
Average	-1.15%	-1.11%	+16.95%	+74.93%	16.45B
Weighted average by Cap.	-1.16%	-0.57%	+24.44%	+83.40%

Grindeks AS Share Price Nasdaq Riga

Stocks

GRD1R

LV0000100659

Pharmaceuticals

Latest news : Grindeks AS

Press Releases: Grindeks AS

Managers and Directors: Grindeks AS

Generic Pharmaceuticals

Company Profile